Loading stock data…
ENGN
$7.25-0.02 (-0.28%)
Market ClosedLast close May 1
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
enGene Therapeutics Inc. in the Healthcare sector is trading at $7.25. The stock is currently 41% below its 52-week high of $12.25, remaining 1.6% below its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why ENGN maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.25
Potential Upside
5%
Whystock Fair Value$7.61
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$23.27+221.0%
Range$9.00 – $30.00
Fundamentals
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$583.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.49%
Volume
Today's trading volume
226,354
Recent News
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference
Executives from enGene (NASDAQ:ENGN) provided an update on the company’s detalimogene program in non-muscle invasive bladder cancer (NMIBC), discussing recent protocol changes, regulatory interactions, and commercial planning as the study advances. Protocol amendments and response-rate improvement
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference
enGene (NASDAQ:ENGN) CEO Ron Cooper said the company’s focus is advancing its DDX platform, a proprietary non-viral gene therapy technology, with its lead program detalimogene being developed for non-muscle invasive bladder cancer (NMIBC). Speaking at a Barclays event moderated by Senior Biotech Ana
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update
enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company’s view that its investigational therapy
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference
enGene (NASDAQ:ENGN) Chief Executive Officer Ron Cooper outlined the company’s near-term regulatory and clinical plans for its lead program, detalimogene voraplasmid, during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences Conference. Cooper said the company expects to provide an
Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)
We recently published an article titled 10 Best Low Volatility Canadian Stocks to Buy. On January 30, Jefferies initiated coverage of enGene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a $28 price target, highlighting the company’s ongoing pivotal study in high-risk non-muscle invasive bladder cancer (NMIBC), with a key data update expected in the […]